The use of buprenorphine in the treatment of chronic pain in the pain clinic

被引:0
|
作者
Jakubow, Piotr [1 ,2 ,3 ]
Kosel, Dariusz [2 ,3 ]
Kosciuczyk, Urszula [2 ,3 ]
Jarocka, Malgorzata [3 ]
Kopczynska, Antonina [3 ]
Domalewska, Aneta [3 ,4 ]
Ejsmont, Anna [3 ,5 ]
机构
[1] Uniwersytet Med Bialymstoku, Zaklad Farmakol Klin, Sklodowskiej 24a, PL-15215 Bialystok, Poland
[2] Uniwersytet Med Bialymstoku, Klin Anestezjol & Intensywnej Terapii, Bialystok, Poland
[3] Poradnia Leczenia Bolu NZOZ Vitamed, Bialystok, Poland
[4] Hosp Stacjonarne Dom Opatrznosci Bozej Bialymstok, Bialystok, Poland
[5] Uniwersytet Med Bialymstoku, Klin Psychiat, Bialystok, Poland
来源
MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE | 2016年 / 8卷 / 02期
关键词
opioids; buprenorphine; noncancer pain;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: The increased use of opioids in the treatment of chronic non-cancer pain has been observed in recent years. Buprenorphine is an opioid analgesic with an established position in pain therapy. Due to the unique pharmacological profile it is attractive to use in the outpatient clinic. The big advantage of the drug is the lack of tolerance induced by opioids and, theoretically, a high safety profile. The aim of the study is to analyse the use and safety profile of buprenorphine in patients with chronic nonmalignant pain at the Outpatient Pain Treatment Clinic. Material and methods: The records of patients treated at the Outpatient Pain Treatment Clinic were subjected to a retrospective analysis, as it was reported to the National Health Fund. Results: Buprenorphine was used in 9% of patients and it represented more than 50% in the group of opioid drugs. The largest group of patients consisted of those with the back pain in the lumbosacral segment. The most demanded choice was transdermal buprenorphine. There were no serious complications or critical side effects. For 3% of patients aged 65 years and more it was necessary to reduce the dose to improve the cognitive function. Due to the skin side effects it was also necessary to rotate the transdermal formulation. Conclusions: Buprenorphine, which is preferred as the treatment of choice in chronic non-malignant pain syndromes, is also effective and safe. The dose and form of the drug should be adjusted to the state and condition of the patient.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [21] Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study
    Mick Serpell
    Shiva Tripathi
    Sabine Scherzinger
    Sònia Rojas-Farreras
    Alexander Oksche
    Margaret Wilson
    The Patient - Patient-Centered Outcomes Research, 2016, 9 : 35 - 46
  • [22] Buprenorphine for Cancer Pain: Is It Ready for Prime Time?
    Prommer, Eric
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2015, 32 (08) : 881 - 889
  • [23] Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV
    Miller, Emily A.
    McGinnis, Kathleen A.
    Edelman, E. Jennifer
    Feinberg, Termeh
    Gordon, Kirsha S.
    Kerns, Robert D.
    Marshall, Brandon D. L.
    Patterson, Julie A.
    McRae, MaryPeace
    AIDS AND BEHAVIOR, 2024, 28 (12) : 3994 - 4004
  • [24] Recommending buprenorphine for pain management
    Ehrlich, Aliza T.
    Darcq, Emmanuel
    PAIN MANAGEMENT, 2019, 9 (01) : 13 - 16
  • [25] Buprenorphine: Considerations for pain management
    Johnson, RE
    Fudala, PJ
    Payne, R
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (03) : 297 - 326
  • [26] Medication use among pediatric patients with chronic musculoskeletal pain syndromes at initial pain clinic evaluation
    Guite, Jessica W.
    Sherry, David D.
    Jarvis, Esther W.
    Lewen, Margaret O.
    Khan, Sarosh
    Kraemer, Francis Wickham
    PAIN MANAGEMENT, 2018, 8 (01) : 15 - 25
  • [27] Buprenorphine and pain treatment in pediatric patients: an update
    Vicencio-Rosas, Erendira
    Gabriela Perez-Guille, Maria
    Flores-Perez, Carmen
    Flores-Perez, Janett
    Trujillo-Jimenez, Francisca
    Luis Chavez-Pacheco, Juan
    JOURNAL OF PAIN RESEARCH, 2018, 11 : 549 - 559
  • [28] When Opioids Fail in Chronic Pain Management: The Role for Buprenorphine and Hospitalization
    Berland, Daniel W.
    Malinoff, Herbert L.
    Weiner, Mark A.
    Przybylski, Robert
    AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (04) : 316 - 321
  • [29] Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis
    Lazaridou, Asimina
    Paschali, Myrella
    Edwards, Robert R.
    Gilligan, Christopher
    PAIN MEDICINE, 2020, 21 (12) : 3691 - 3699
  • [30] Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch
    Stanicic, Filip
    Grbic, Dimitrije
    Vukicevic, Djurdja
    Zah, Vladimir
    PAIN MANAGEMENT, 2024, 14 (01) : 35 - 48